COMMUNIQUÉS West-GlobeNewswire

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
01/09/2026
BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will [...]
Dianthus Therapeutics to Participate in Three Investor Conferences During September
01/09/2026
NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Eyconis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
01/09/2026
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a clinical-stage biotechnology company advancing next-generation, long-acting ophthalmic therapeutics, today announced that members of its [...]
Vor Bio To Participate in Upcoming September Conferences
01/09/2026
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the [...]
Recovery Month Shines a Light on Hope, Healing, and the Power of Personalized Care at Futures Recovery Healthcare
01/09/2026
TEQUESTA, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- In recognition of National Recovery Month, Futures Recovery Healthcare is celebrating the resilience of individuals and families affected by substance use and mental [...]
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
01/09/2026
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
Scribe Therapeutics to Participate in Upcoming Investor Conferences
01/09/2026
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed [...]
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
01/09/2026
Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND Submission MIAMI, Sept. 01, 2026 (GLOBE [...]
Elevar Therapeutics to Share Camrelizumab/Rivoceranib Poster at International Liver Cancer Association Conference on Clinical Outcomes in Younger Age Patients with Unresectable Hepatocellular Carcinoma
01/09/2026
In post hoc analysis of CARES-310 trial, combination improved mPFS versus sorafenib across age subgroups Combination also improved mOS versus sorafenib in patients <50 years and ≥50 years Elevar is sponsoring Sept. 3 [...]
Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President
01/09/2026
TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI [...]
Cabaletta Bio to Participate in Upcoming Investor Conferences
01/09/2026
PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically [...]
BICEL™ SOFT TIP I/A terralution™. Gentle by Design. Sustainable by Nature*.
01/09/2026
Medicel AG expands its SOFT TIP I/A portfolio with the launch of BICEL™ SOFT TIP I/A terralution™ – bimanual sustainable I/A (irrigation / aspiration) for gentle tissue interaction – at the ESCRS Congress 2026 in London [...]
The Insides Company franchit une nouvelle étape vers le remboursement de son dispositif médical The Insides System® en France
01/09/2026
La Haute Autorité de Santé rend un avis favorable à l’inscription de The Insides System® sur la Liste des Produits et Prestations Remboursables (LPPR), franchissant une étape décisive vers une prise en charge pérenne [...]
Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
01/09/2026
Ingelheim, Germany, and Bracknell, United Kingdom SCOVELLA® is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies 1 , targeting the key [...]
Transactions in connection with share buy-back program
01/09/2026
Company announcement no. 33 - 26 01 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
ENA Respiratory Awarded Biointelect Venturer Funding to Support New Study in Asthma Patients of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
01/09/2026
MELBOURNE, Australia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral [...]
Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S.
01/09/2026
Partnership will support Resolution’s pivotal clinical program in 2027, as well as future commercial preparedness for RTX001, its lead asset in patients with end-stage liver disease (ESLD) Primary goal is to ensure [...]
Bavarian Nordic Launches First Tranche of New Share Buy-Back Program
01/09/2026
COPENHAGEN, Denmark, September 1, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the new share buy-back program announced on August 21, under which the Company intends to repurchase own [...]
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
01/09/2026
Ad hoc announcement pursuant to Art. 53 LR REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with relapsing multiple sclerosis (RMS) 1 [...]

Pages